A Study of DR-01 in Subjects With Alopecia Areata and Vitiligo

Phase 1 Active not recruiting 81 enrolled Dren Bio

RandomizedParallel-groupOpen-labelTreatment

Summary

This is a multi-center, parallel-group, open-label, randomized, Phase 1b study to explore the safety, clinical activity, pharmacokinetics and pharmacodynamics of DR-01 in adults with Alopecia Areata or Vitiligo.

Timeline

Start: 2024-10-30
Primary completion: 2027-05
Completion: 2027-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dibotatug	Monoclonal antibody	—	Intravenous

A Study of DR-01 in Subjects With Alopecia Areata and Vitiligo

Summary

Timeline

Drugs

Indications